Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drop trial offers hope for chronic dry eye sufferers

NCT ID NCT07224529

Recruiting now Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a prescription eye drop called Vevye (cyclosporine 0.1%) in 48 adults with meibomian gland dysfunction (MGD), a common cause of dry, burning eyes. Participants use the drops twice daily for 24 weeks, and researchers measure changes in eye symptoms, gland function, and eye surface health. The goal is to see if Vevye can improve both symptoms and signs of MGD, potentially offering a new treatment option.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEIBOMIAN GLAND DYSFUNCTION (MGD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome Meibomian Gland Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MEIBOMIAN GLAND DYSFUNCTION (MGD)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Alabama at Birmingham, School of Optometry, Clinical Eye Research Facility

    RECRUITING

    Birmingham, Alabama, 35294, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••